<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 1, Open-Label, Dose-Finding Study of INCB050465 (PI3K&delta; Inhibitor) in Combination<br> With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-showx2" href="images/study-rationale/Incyte ASCO 2017 TS mockup INC-1242 citadel-102.jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav3">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav3">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav3">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top3" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content3">
				<!-- section 1 -->
				<div id="po3" style="height: 50px; width: 100%;"></div>
				<br>
				<div class="scroll-wrapper" style="position: relative;">
					<div>
						<div class="absolute-cen">
						<h3 id="po3">Primary objective:</h3>
						<ul id="po3">
							<li>Evaluate safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab</li>
							</ul>
							<!--<h3 id="po3">secondary objectives:</h3>
							<ul>
							<li>Evaluate ORR, CRR, duration of response, PFS, and OS </li>
							<li>Evaluate the PK of INCB050465 in combination with bendamustine and obinutuzumab</li>
						</ul>-->
						</div>
					</div>
					<div id="po3"></div>
					<!-- section 2 -->
					<div id="sd3">
						<div class="absolute-cenx">
						<h3>Study Design</h3>

						<img class="img-responsive" src="images/study-design/INCB050465_study_design_chart_1.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					
					<!-- section 3 -->
					<div id="kiec3">
						<div class="absolute-cen">
						<h3 >Key inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>Histologically confirmed, CD20+ FL R/R to rituximab-containing regimen</li>
							<li>Previously treated with a maximum of 4 cancer-directed treatment regimens</li>
							<li>≥1 measurable lesion >1.5 cm in at least one dimension on computed tomography or magnetic resonance imaging</li>
							<li>Eastern Cooperative Oncology Group performance status 0 to 2</li>
						</ul>
						<br>
						<h3>Key exclusion criteria:</h3>
						<ul>
							<li>Transformation to a more aggressive form of lymphoma or Grade 3B FL</li>
							<li>History of or central nervous system lymphoma (primary or metastatic)</li>
							<li>Allogeneic stem cell transplant within last 6 months, or active graft-versus-host disease following allogeneic or autologous stem cell transplant within last 3 months</li>
							<li>Prior treatment with a selective PI3K&delta; inhibitor (eg, idelalisib) or a pan-PI3K inhibitor</li>
							<li>Prior treatment with obinutuzumab</li>
							<li>Prior treatment with bendamustine (>12 months before the start of study), unless specific criteria are met<sup>†</sup></li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm3" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p><sup>†</sup>Subjects with prior bendamustine treatment (greater than 12 months before the start of study treatment) are eligible if they meet the following criteria:
did not discontinue because of tolerability concerns, achieved either partial or CR to the bendamustine regimen of at least 12 months in duration before
relapse/progression, experienced progression following a regimen containing an alkylating agent.
<br>
CITADEL = Clinical Investigation of Targeted PI3K-delta Inhibition in Lymphomas, CRR = complete response rate, DOR = duration of response, FL = follicular lymphoma, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, PI3K = phosphatidylinositol-3 kinase, R/R = relapsed/refractory
</p>
</div>